US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

26.98

0.0000

Volume:8

Turnover:218.44

Market Cap:2.43M

PE:- -

High:26.98

Open:26.98

Low:26.98

Close:26.98

52wk High:28.62

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.23

T/O Rate:0.01%

Dividend:0.45

Dividend Rate:1.67%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

PegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates

BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics

Celcuity To Participate in Upcoming Investor Conferences

Satellos to Participate in Upcoming Investor Conferences

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

FutureChem sets final issue price for paid-in capital increase

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210

Vogenx initiated with a Buy at Jones

SciSparc subsidiary provides update on SCI-210 trial enrollment

PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

Takeda receives FDA approval of NDA for Mimrylo

Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup

Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative

Simply Wall St.

NeuroThera Labs Hires European IR Firm to Expand Investor Reach

Oppenheimer biotech analysts hold an analyst/industry conference call

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/NVIB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":26.9817,"timestamp":1788357058682,"preClose":26.9817,"halted":0,"volume":8,"delay":0,"changeRate":0,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"09-02 09:52:42 EDT","open":26.9817,"high":26.9817,"low":26.9817,"amount":218.44,"amplitude":0,"askPrice":27.38,"askSize":100,"bidPrice":27.32,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":26.9817,"nav":27.453,"aum":2470820.32,"dividendRate":0.016747,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.4504,"preClose":26.9817,"latestTime":"16:10 EDT","volume":6,"amount":161.8902,"timestamp":1788293404457,"change":0.4687,"changeRate":0.017371,"amplitude":0},"volumeRatio":0.230858},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.230858,"shares":90001,"dividePrice":0.45187,"high":26.9817,"amplitude":0,"preClose":26.9817,"low":26.9817,"week52Low":24.54,"pbRate":"--","week52High":28.621,"institutionHeld":0,"latestPrice":26.9817,"eps":0,"divideRate":0.016747,"volume":8,"delay":0,"ttmEps":0,"open":26.9817,"prevYearClose":25,"prevWeekClose":27.0104,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":26.097,"twentyDayClose":27.7429},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664890506","title":"PegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890506","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664890506?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:08","pubTimestamp":1788340086,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. Class H ( ($HK:2565) ) has shared an update. PegBio has entered a material transfer agreement with Korean biotech SN BioScience to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pegbio-partners-sn-bioscience-to-advance-long-acting-metabolic-peptide-candidates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pegbio-partners-sn-bioscience-to-advance-long-acting-metabolic-peptide-candidates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","SN","LU0128526141.USD","LU2242644610.SGD","BK4191","LU0029874061.USD","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285768","title":"BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285768","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285768?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:26","pubTimestamp":1788272819,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. BioMarin Pharmaceutical Inc. has completed the acquisition of Dutch biotech comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4139","BK4539","BK4007","LENZ","XBI","BK4585","BK4588","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851222","title":"Celcuity To Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851222","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851222?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:30","pubTimestamp":1788265800,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Sept.  01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354143/0/en/celcuity-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664085583","title":"Satellos to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664085583","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664085583?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative mus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353948/0/en/satellos-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","NVIB","HYLG","MEDX","IDNA","BK4139","GDOC","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985383","title":"Novartis halts autoimmune CAR-T trials following three deaths, Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985383","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664985383?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258648,"startTime":"0","endTime":"0","summary":"Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after thr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765489.SGD","BMED","IE00B2B36J28.USD","IE0002141913.USD","SYNB","TBXU","LU0211331839.USD","IBBQ","IE00BFTCPJ56.SGD","NVIB","PPH","BK4007","IE00B4R5TH58.HKD","LU0070302665.USD","HYLG","IE0009355771.USD","LU0208291251.USD","BK4588","CNCR","LFSC","IE00BJT1NW94.SGD","NVS","IBB","GDOC","BK4532","BK4585","FBT","GNOM","IE00BJJMRZ35.SGD","BK4578","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887912","title":"FutureChem sets final issue price for paid-in capital increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887912?lang=en_us&edition=fundamental","pubTime":"2026-09-01 10:46","pubTimestamp":1788230764,"startTime":"0","endTime":"0","summary":"FutureChem Co., Ltd. ( ($KR:220100) ) has issued an announcement. FutureChem Co., Ltd., a KOSDAQ-listed radiopharmaceutical and biotech company, ha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881893","title":"Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881893","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881893?lang=en_us&edition=fundamental","pubTime":"2026-09-01 07:30","pubTimestamp":1788219000,"startTime":"0","endTime":"0","summary":"An Important Step Forward for Access to LEQEMBI for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353756/0/en/canada-s-drug-agency-issues-final-positive-recommendation-supporting-public-reimbursement-of-leqembi-lecanemab-for-early-alzheimer-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HYLG","NVIB","SOCL","BMED","IDNA","MEDX","MCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883188","title":"NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883188?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:37","pubTimestamp":1788208671,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs reported strong enrollment momentum in its SCI-210 clinical trial for ch...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-advances-enrollment-in-autism-drug-trial-for-sci-210?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-advances-enrollment-in-autism-drug-trial-for-sci-210?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","NVIB","IDNA","GDOC","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883886","title":"Vogenx initiated with a Buy at Jones","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883886?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:15","pubTimestamp":1788207318,"startTime":"0","endTime":"0","summary":"Jones initiated coverage of Vogenx (VOGX) with a Buy rating and $55 price target Vogenx is a clinical-stage metabolic-focused biotech company, with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOGX","NVIB","XBIX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883858","title":"SciSparc subsidiary provides update on SCI-210 trial enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883858","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883858?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207046,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC)announced that NeuroThera Labs continued advancement in participant enrollment for the clinical trial assessing NeuroThera’s SCI-210...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-subsidiary-provides-update-on-sci-210-trial-enrollment-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-subsidiary-provides-update-on-sci-210-trial-enrollment-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4007","MEDX","SPRC","BK4139","HYLG","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831883","title":"PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831883","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831883?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:05","pubTimestamp":1788206710,"startTime":"0","endTime":"0","summary":"PMV Pharmaceuticals (PMVP) announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pmv-pharmaceuticals-announces-updated-ovarian-cancer-data-from-pynnacle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pmv-pharmaceuticals-announces-updated-ovarian-cancer-data-from-pynnacle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","HYLG","IDNA","GDOC","PMVP","BK4139","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663588047","title":"Protagonist announces Takeda received U.S. FDA approval for MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663588047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663588047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 04:35","pubTimestamp":1788122107,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","RSPH","BK4585","TBXU","TAK","BK4139","SYNB","PINK","GNMX","XLVX","PSCH","IBB","BBP","BK4007","FRTY","TECB","MRNY","MEDI","IEIH","MRNX","LFSC","NVIB","LABU","PTGX","BK4588","IDNA","GDOC","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663404203","title":"Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103","url":"https://stock-news.laohu8.com/highlight/detail?id=2663404203","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663404203?lang=en_us&edition=fundamental","pubTime":"2026-08-31 03:35","pubTimestamp":1788118510,"startTime":"0","endTime":"0","summary":"Tenax Therapeutics (TENX) announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hyp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GDOC","IDNA","LENZ","BK4007","NVIB","HYLG","TENX","MEDX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019703","title":"Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019703","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019703?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:52","pubTimestamp":1787964735,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an announcement. Takeda has secured U.S. FDA approval for MIMRYLO (rusfertide), a first-in-cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IDNA","MRNX","XLVX","TECB","NVIB","LABU","TBXU","FRTY","SYNB","BBP","BMED","PINK","MRNY","BK4588","IEIH","PSCH","MEDI","IYH","RSPH","GNMX","IBB","GDOC","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016033","title":"Takeda receives FDA approval of NDA for Mimrylo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016033?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:00","pubTimestamp":1787958013,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia ve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","MRNX","IYH","FRTY","GNMX","MRNY","LABU","GDOC","IBB","MEDI","NVIB","PSCH","LFSC","BK4007","BBP","BK4588","BK4585","RSPH","BMED","TECB","TBXU","IDNA","TAK","SYNB","XLVX","PINK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663015241","title":"Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2663015241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663015241?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:22","pubTimestamp":1787952120,"startTime":"0","endTime":"0","summary":"Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to interest-rate movements.BioNTech shares slid after the biotech firm scrapped a clinical trial for its mRNA cancer vaccine, marking the second setback this year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4588","NVIB","XLV","BK4581","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705792","title":"Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705792","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705792?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:22","pubTimestamp":1787898153,"startTime":"0","endTime":"0","summary":"Repligen recently reported past second-quarter 2026 results that exceeded earnings and revenue expectations and raised its full-year 2026 guidance, highlighting broad year-over-year growth across filtration, chromatography, proteins, and process analytics.\nAn interesting detail is that this operational momentum, accompanied by higher full-year forecasts and rising analyst estimates, may reinforce perceptions of Repligen’s business strength across multiple bioprocessing franchises.\nWe’ll now...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0012050646.USD","LU0106261612.USD","LU0205194284.USD","BK4121","RGEN","LU1815336091.USD","XBIX","NVIB","LU0757428866.USD","LU0205193047.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662403754","title":"NeuroThera Labs Hires European IR Firm to Expand Investor Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2662403754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662403754?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:02","pubTimestamp":1787878968,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an announcement. NeuroThera Labs Inc., a clinical-stage biotech subsidiary of SciSparc Ltd. listed ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","EPV","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662871430","title":"Oppenheimer biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662871430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662871430?lang=en_us&edition=fundamental","pubTime":"2026-08-28 02:00","pubTimestamp":1787853615,"startTime":"0","endTime":"0","summary":"Biotech Analysts, along with the Co-Director of Stanford Amyloid Cente, discuss the full results from AZN/IONS‘s CARDIO-TTRansform trial on an Anal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBI","BK4588","XBIX","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085942","title":"AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085942","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085942?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:01","pubTimestamp":1787835660,"startTime":"0","endTime":"0","summary":"Video webcast now availablehere OCALA, Fla., Aug.  27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM” or the “Company”) today announced that it participated in the Virtual Inv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352073/29489/en/aim-immunotech-participates-in-the-virtual-investor-why-now-on-demand-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","HYLG","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":142,"code":"91000000","status":"200"}]}}